» Articles » PMID: 19395337

Delivery of Peptide and Protein Drugs over the Blood-brain Barrier

Overview
Journal Prog Neurobiol
Specialty Neurology
Date 2009 Apr 28
PMID 19395337
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Peptide and protein (P/P) drugs have been identified as showing great promises for the treatment of various neurodegenerative diseases. A major challenge in this regard, however, is the delivery of P/P drugs over the blood-brain barrier (BBB). Intense research over the last 25 years has enabled a better understanding of the cellular and molecular transport mechanisms at the BBB, and several strategies for enhanced P/P drug delivery over the BBB have been developed and tested in preclinical and clinical-experimental research. Among them, technology-based approaches (comprising functionalized nanocarriers and liposomes) and pharmacological strategies (such as the use of carrier systems and chimeric peptide technology) appear to be the most promising ones. This review combines a comprehensive overview on the current understanding of the transport mechanisms at the BBB with promising selected strategies published so far that can be applied to facilitate enhanced P/P drug delivery over the BBB.

Citing Articles

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.

Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.

PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.


Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly.

Kalmouni M, Oh Y, Alata W, Magzoub M Pharmaceutics. 2024; 16(11).

PMID: 39598566 PMC: 11597747. DOI: 10.3390/pharmaceutics16111443.


Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases.

Ozceylan O, Sezgin-Bayindir Z ACS Omega. 2024; 9(33):35223-35242.

PMID: 39184484 PMC: 11340000. DOI: 10.1021/acsomega.4c01774.


Development of a Fluorescent Ligand for the Intracellular Allosteric Binding Site of the Neurotensin Receptor 1.

Vogt H, Shinkwin P, Huber M, Staffen N, Hubner H, Gmeiner P ACS Pharmacol Transl Sci. 2024; 7(5):1533-1545.

PMID: 38751637 PMC: 11092115. DOI: 10.1021/acsptsci.4c00086.


Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.

Kakoty V, Sarathlal K, Kaur P, Wadhwa P, Vishwas S, Khan F Neurol Sci. 2023; 45(4):1409-1418.

PMID: 38082050 DOI: 10.1007/s10072-023-07253-2.